Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

ClinicalTrials.gov ID: NCT01073163

Public ClinicalTrials.gov record NCT01073163. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Study identification

NCT ID
NCT01073163
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Cephalon
Industry
Enrollment
54 participants

Conditions and interventions

Interventions

  • Bendamustine Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2010
Primary completion
May 31, 2012
Completion
May 31, 2012
Last update posted
Apr 23, 2014

2010 – 2012

United States locations

U.S. sites
36
U.S. states
24
U.S. cities
35
Facility City State ZIP Site status
Hematology Oncology Physicans Extenders Group Tucson Arizona
University of Arkansas for Medical Sciences Little Rock Arkansas
St. Jude Heritage Medical Group Fullerton California
Comprehensive Cancer Center Palm Springs California
University of Colorado Cancer Center Aurora Colorado
Rocky Mountain Cancer Center Denver Colorado
The Hospital of Central Connecticut New Britain Connecticut
Cancer Center of Central Connecticut Southington Connecticut
Memorial Cancer Institute Hollywood Florida
Cancer Centers of Florida Orlando Florida
MD Anderson Cancer Cnt Orlando Orlando Florida
John B Amos Cancer Center Columbus Georgia
St Francis Cancer Research Foundation Beech Grove Indiana
Cedar Valley Medical Specialists Waterloo Iowa
Cancer Center of Kansas Wichita Kansas
University of Kentucky Lexington Kentucky
LSU Health Sciences Center - Shreveport Shreveport Louisiana
MaineGeneral Medical Center Augusta Maine
Missouri Cancer Associates Columbia Missouri
Kansas City Cancer Center Kansas City Missouri
UNM Cancer Center/New Mexico Cancer Care Alliance Albuquerque New Mexico
Interlakes Foundation, Inc Rochester New York
SUNY Upstate / Upstate Medical University Syracuse New York
Willamette Valley Cancer Center Springfield Oregon
Geisinger Medical Center Danville Pennsylvania
Pennsylvania Oncology Hematology Associates, Inc. Philadelphia Pennsylvania
Charleston Hematology Oncology, PA Charleston South Carolina
Sarah Cannon Cancer Center Nashville Tennessee
Texas Oncology, P.A. Fort Worth Texas
Cancer Care Center of South Texas San Antonio Texas
Texas Oncology Tyler Texas
Virginia Oncology Associates Norfolk Virginia
Cancer Outreach Asscociates, PC Richlands Virginia
Cancer Care Northwest-South Spokane Washington
Northwest Cancer Specialists, PC Vancouver Washington
West Virginia University School of Medicine Morgantown West Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01073163, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 23, 2014 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01073163 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →